Factors associated with failure to achieve a glycated haemoglobin target of <8.0% in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

T. C. Drake, F. C. Hsu, D. Hire, S. H. Chen, R. M. Cohen, R. Mcduffie, E. Nylen, P. O'Connor, S. Rehman, E. R. Seaquist

Research output: Contribution to journalLetterpeer-review

10 Scopus citations

Abstract

The aim of this study was to identify the clinical features of participants in the standard therapy arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) glycaemia trial who failed to reach the glycated haemoglobin (HbA1c) target. We analysed 4685 participants in the standard therapy arm, comparing participants who reached the HbA1c target of <8.0% with those whose HbA1c level was ≥8.0% 12months after randomization. Baseline and 12-month clinical characteristics were compared. At 12months after randomization, 3194 participants had HbA1c <8.0% and 1491 had HbA1c ≥8.0%. Black race [odds ratio (OR) 0.74, 95% confidence interval (CI) 0.61-0.89; p=0.002], severe hypoglycaemia (OR 0.57, CI 0.37-0.89; p=0.014) and insulin use (OR 0.51, CI 0.40-0.65; p<0.001) were associated with failure to reach HbA1c goal at 12months in the adjusted model. Even with free medications, free visits with clinicians and aggressive titration of medications, >30% of participants in the standard arm of the ACCORD trial had an HbA1c ≥8.0% at 1year. Participants who were black, had severe hypoglycaemia and were on insulin were more likely to have an above-target HbA1c concentration after 12months on the standard protocol.

Original languageEnglish (US)
Pages (from-to)92-95
Number of pages4
JournalDiabetes, Obesity and Metabolism
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2016

Keywords

  • Antidiabetic drug
  • Clinical trial
  • Cost-effectiveness
  • Diabetes complications
  • Insulin therapy
  • Type 2 diabetes

Fingerprint Dive into the research topics of 'Factors associated with failure to achieve a glycated haemoglobin target of <8.0% in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial'. Together they form a unique fingerprint.

Cite this